{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023528","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.086294+00:00","generated_at":"2026-06-22T01:12:44.442012+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX","bullets":["Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.","OASIS Phase 1/2a met primary safety endpoint; no serious adverse events in 27 wet AMD patients.","Cohorts 3/4: 88% injection-free to Month 5, 75% to Month 6; >90% reduction in treatment burden.","Company expects to initiate Phase 2 trial for CLS-AX in wet AMD in Q1 2023.","Entered royalty interest sale with HealthCare Royalty for up to $65M non-dilutive funding; cash $53.4M, runway into 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023528","json":"https://secwatch.observer/filing/0000950170-22-023528.json","markdown":"https://secwatch.observer/filing/0000950170-22-023528.md","text":"https://secwatch.observer/filing/0000950170-22-023528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/0000950170-22-023528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/clsd-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:12:44.442012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f90acfb4f961ef1d0f5fc2510b31f22ac87a4065","claim":"Clearside Biomedical, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.3 million, net income $7.8 million, EPS $0.13 per share of common stock.","evidence_excerpt":"Clearside’s license and other revenue for the third quarter of 2022 was $0.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/0000950170-22-023528-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$7.8 million"},{"label":"EPS","value":"$0.13 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}